Avadel Pharmaceuticals (AVDL) Change in Accured Expenses: 2009-2024
Historic Change in Accured Expenses for Avadel Pharmaceuticals (AVDL) over the last 16 years, with Dec 2024 value amounting to $16.4 million.
- Avadel Pharmaceuticals' Change in Accured Expenses fell 165.40% to -$4.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $227,000, marking a year-over-year decrease of 74.64%. This contributed to the annual value of $16.4 million for FY2024, which is 2.77% down from last year.
- Per Avadel Pharmaceuticals' latest filing, its Change in Accured Expenses stood at $16.4 million for FY2024, which was down 2.77% from $16.9 million recorded in FY2023.
- Over the past 5 years, Avadel Pharmaceuticals' Change in Accured Expenses peaked at $16.9 million during FY2023, and registered a low of -$13.2 million during FY2020.
- Over the past 3 years, Avadel Pharmaceuticals' median Change in Accured Expenses value was $16.4 million (recorded in 2024), while the average stood at $11.2 million.
- Its Change in Accured Expenses has fluctuated over the past 5 years, first crashed by 3,804.76% in 2020, then skyrocketed by 7,341.41% in 2023.
- Avadel Pharmaceuticals' Change in Accured Expenses (MRY) stood at -$13.2 million in 2020, then soared by 106.77% to $895,000 in 2021, then crashed by 74.64% to $227,000 in 2022, then soared by 7,341.41% to $16.9 million in 2023, then dropped by 2.77% to $16.4 million in 2024.
- Its last three reported values are $16.4 million in FY2024, $16.9 million for FY2023, and $227,000 during FY2022.